Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11867356 | 0.93 | PTGS1 (0.63) | PTGS1GSTK1NOD1SLC6A5GLO1 | |
| Linoleic Acid SCHEMBL28319711 | 0.88 | PTGS1 (0.66) | PTGS1GSTK1NOD1SLC6A5EPHX2 | |
| Linoleic Acid SCHEMBL28965215 | 0.88 | PTGS1 (0.66) | PTGS1GSTK1NOD1SLC6A5EPHX2 | |
| SCHEMBL1356324 | 0.85 | PTGS1 (0.51) | PTGS1GSTK1NOD1GLO1 | |
| SCHEMBL2928607 | 0.85 | PTGS1 (0.68) | PTGS1GSTK1NOD1GLO1 | |
| SCHEMBL9421282 | 0.82 | PTGS1 (0.74) | PTGS1GSTK1NOD1GLO1 | |
| SCHEMBL10803638 | 0.81 | PTGS1 (0.63) | PTGS1GSTK1NOD1GLO1 | |
| SCHEMBL8774782 | 0.81 | PTGS1 (0.63) | PTGS1GSTK1NOD1GLO1 | |
| SCHEMBL9817304 | 0.81 | PTGS1 (0.63) | PTGS1GSTK1NOD1GLO1 | |
| SCHEMBL10801547 | 0.81 | PTGS1 (0.63) | PTGS1GSTK1NOD1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519246-A1 | TOPICAL ACYL GLUTATHIONE PSORIASIS FORMULATIONS | Perricone, Nicholas V. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011081715-A1 | TOPICAL ACYL GLUTATHIONE PSORIASIS FORMULATIONS | PERRICONE NICHOLAS V (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160143-A1 | Topical Acyl Glutathione Psoriasis Compositions | N.V. PERRICONE LLC | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160143-A1 | Topical Acyl Glutathione Psoriasis Compositions | GSTA2, GSTA1, GSTM2 | PTGS1 72/4885GSTK1 7/4885NOD1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.